Genenta Science

We are a clinical-stage biotechnology company pioneering the treatment of cancers with a technology platform that allows the direct delivery of immunotherapeutic payloads within the tumor microenvironment. Intrinsic resistance significantly reduces the effectiveness of most cancer treatments, including leading-edge technologies such as checkpoint inhibitors and CAR-T cell therapies. Our delivery system takes advantage of a subset of tumor-associated macrophages called TEMs (Tie-2 expressing monocytes) which normally have an affinity for and travel to tumors, and turns them into a “Trojan Horse” to deliver an immunotherapeutic payload within tumors, where it can steer the natural immune responses towards anti-cancer-combat mode. Our leading product candidate has moved into Phase l/IIa clinical trials in glioblastoma and is poised to impact other hard-to-treat cancer types.